Feinstein Institutes Awarded $11.3M Subcontract for COVID-19 Antibody Research

MANHASSET, N.Y.--(BUSINESS WIRE)-- The Feinstein Institutes for Medical Research has been awarded a multi-year subcontract from The Frederick National Laboratory for Cancer Research (FNL), currently operated by Leidos Biomedical Research, Inc. for the National Cancer Institute (NCI), to establish a Capacity Building Center (CBC) to further develop and deploy serological (antibody) testing assays for the novel coronavirus disease 2019 (COVID-19). Working with Northwell Health Laboratories, this facility – one of four such centers in the country – will also pursue research studies of the immune system response to the disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201104005375/en/

Dr. Peter Gregersen (Credit: The Feinstein Institutes for Medical Research)

Dr. Peter Gregersen (Credit: The Feinstein Institutes for Medical Research)

The funding awarded by the NCI’s Serological Sciences Network (SeroNet) was established using funds from the Paycheck Protection Program and Health Care Enhancement Act appropriation of $306 million to develop, validate, improve, and implement serological testing. The Feinstein Institutes will work in close partnership with the FNL Serology Laboratory and three other CBC research institutions to support the overall goals of SeroNet.

Each CBC will tackle three main antibody testing goals, including the standardization of tests, developing better, more sensitive assays, and methods needed to conduct large-scale testing to identify those who may have been infected or exposed to the virus. Each center expects to test and return results to at least 5,000 people each week. Northwell Health Laboratories is already performing about 14,000 antibody tests per week. The Feinstein Institutes will develop new testing assays in collaboration with SeroNet, and further characterize the role of antibody testing for both patient care and population health.

“To better understand the course of COVID-19 and its impact on patient’s bodies, we must develop more efficient and accurate antibody tests and integrate them with a deeper understanding of the disease,” said Peter K. Gregersen, MD, principal investigator of the CBC and professor at the Feinstein Institutes. “It is exciting to have the support of the NCI and the SeroNet collaborations in order to contribute to this goal.”

Researchers will also study the molecular mechanisms driving serological, humoral, and cellular immune responses to the virus. These discoveries will hopefully lead to a better understanding of treatments and therapeutic development. As part of the SeroNet, each research institution will share data, resources, and samples. The groups’ effort will develop a plan to scale up high-quality, serological testing to meet the emerging national need and collaborate on long-term studies.

“Northwell and Feinstein’s research leadership in New York’s COVID-19 surge provided crucial foundational knowledge during the early stages of the pandemic,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “This project will now harness the tens of thousands of blood samples to further unravel the immunological mechanisms of this disease.”

Leading through the pandemic

Northwell Health, the New York's largest health care provider, was the epicenter of the COVID-19 pandemic at the height of the crisis. To date, more than 95,000 patients were treated across the health system. Of that, more than 16,000 patients were treated as inpatients, nearly 20 percent of all COVID-19 patients in New York State.

Throughout the crisis, and beyond, Northwell Health continues to drive innovative research and cutting-edge care to combat the COVID-19 virus.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Matthew Libassi
516-465-8325
mlibassi@northwell.edu

 
 

Source: Northwell Health

Smart Multimedia Gallery

Dr. Peter Gregersen (Credit: The Feinstein Institutes for Medical Research)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20201104005375/en

Back to news